1. Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply 
Arlene Chan, Marc Buyse, Bin Yao 
The Lancet Oncology 
Volume 17, Issue 5, Pages e176-e177 (May 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure
Disease-free survival in patients 24 months after treatment with neratinib or placebo after trastuzumab-based adjuvant therapy
The Lancet Oncology  , e176-e177DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions